Atea Pharmaceuticals, Inc. key statistics and ratios

In fiscal 2021, Atea Pharmaceuticals, Inc. had return on equity of 19.3%, an operating margin of 39.4%, debt equal to 0.0% of equity and a current ratio of 13.58. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Atea Pharmaceuticals, Inc.: financial ratios, annual
Fiscal year	2020Dec 2020	2021Dec 2021
Operating margin	−22.7%	39.4%
Net margin	−22.5%	34.5%
Free-cash-flow margin	610.1%	−24.8%
Return on equity	−2.0%	19.3%
Return on assets	−1.3%	14.8%
Asset turnover	0.06	0.43
Current ratio	2.73	13.58
Debt to equity	0.0%	0.0%
Effective tax rate	—	12.6%
R&D as % of revenue	78.2%	47.6%
Capital spending as % of revenue	0.1%	0.0%
Free cash flow ÷ net income	—	−71.8%

US$ thousands unless shown otherwise. Fiscal quarters.

Atea Pharmaceuticals, Inc.: financial ratios, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021
Operating margin	46.5%	14.4%	−67.5%	63.1%
Net margin	46.5%	2.5%	−85.9%	60.9%
Current ratio	3.30	3.18	3.22	13.58
R&D as % of revenue	40.3%	65.9%	131.1%	30.1%

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Atea Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Atea Pharmaceuticals, Inc.